Sean Mackay

Sean Mackay

CEO & Co-Founder

Sean Mackay co-founded and leads IsoPlexis as CEO. IsoPlexis’ mission is to provide widely accessible cellular proteomics to speed personalized, curative medicines. The company focuses on shifting paradigms in cell and gene therapy, cancer immunology, and infectious disease towards more patient specific, long lasting treatments. IsoPlexis’ easy to use instrumentation and software have won numerous awards and are used globally to advance precision medicine.

Previously, Sean helped incubate Kleiner Perkins-backed Lifesquare, which connected patients, payers, and providers through sharing essential healthcare information.  Additionally, through work at Lazard and with several early-stage ventures, he developed a passion for helping life sciences and medical device companies manage in times of strategic change, to deliver their highly needed products to the clinical ecosystem. Sean has co-authored a number of publications centered around immune medicines and holds patents for a number of single-cell products worldwide.

2020-08-24T17:02:23-04:00